ID   SU-DHL-4/12V
AC   CVCL_KU32
SY   DHL-4/12V
DR   cancercelllines; CVCL_KU32
DR   Wikidata; Q54970719
RX   PubMed=18357372;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC   Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr646Ser (c.1937A>C) (Y641S); ClinVar=VCV000376218; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr666Asn (c.1996T>A) (Y661N); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peritoneal effusion; UBERON=UBERON_0001268.
DI   NCIt; C36080; Diffuse large B-cell lymphoma germinal center B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0539 ! SU-DHL-4
SX   Male
AG   38Y
CA   Cancer cell line
DT   Created: 22-08-17; Last updated: 05-10-23; Version: 15
//
RX   PubMed=18357372; DOI=10.3892/or.19.4.889;
RA   Pop I., Pop L., Vitetta E.S., Ghetie M.-A.;
RT   "Generation of multidrug resistant lymphoma cell lines stably
RT   expressing P-glycoprotein.";
RL   Oncol. Rep. 19:889-895(2008).
//